Engaging cancer patients in genomic testing decisions
Washington University Participant Engagement and Cancer Genomic Sequencing Center (WU-PE-CGS)
NA · Washington University School of Medicine · NCT06340646
This study is testing if letting cancer patients choose what genetic information they want to receive helps them feel more informed and satisfied with their health decisions.
Quick facts
| Phase | NA |
|---|---|
| Study type | Interventional |
| Enrollment | 990 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Washington University School of Medicine (other) |
| Locations | 1 site (St Louis, Missouri) |
| Trial ID | NCT06340646 on ClinicalTrials.gov |
What this trial studies
The WU-PE-CGS project aims to enhance the involvement of cancer patients and survivors in research by allowing them to choose the types of genomic results they wish to receive. This study focuses on patients with cholangiocarcinoma, multiple myeloma, and early onset colon or rectal cancer, particularly among African-American individuals. The Engagement Optimization Unit will assess how this direct engagement influences participants' knowledge, expectations, personal utility, and decision-making conflicts regarding their health. By building a scientific evidence base, the study seeks to improve patient satisfaction and health outcomes.
Who should consider this trial
Good fit: Ideal candidates include African-American patients diagnosed with cholangiocarcinoma, multiple myeloma, or early onset colon or rectal cancer who are at least 18 years old.
Not a fit: Patients outside the specified demographics or those with other types of cancer may not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could empower patients with cancer to make informed decisions about their genomic information, potentially improving their health outcomes and satisfaction.
How similar studies have performed: While the engagement of patients in genomic testing is a growing area of interest, this specific approach is novel and has not been extensively tested in similar studies.
Eligibility criteria
Show full inclusion / exclusion criteria
Eligibility Criteria: * Patients with cholangiocarcinoma, multiple myeloma, or early onset colon or rectal cancer. * If diagnosed with multiple myeloma, must be African-American. * If diagnosed with colon or rectal cancer, must be African-American AND must be no older than 65 years old at the time of diagnosis. * At least 18 years old * Able to understand and willing to sign an IRB-approved written informed consent document
Where this trial is running
St Louis, Missouri
- Washington University School of Medicine — St Louis, Missouri, United States (RECRUITING)
Study contacts
- Principal investigator: Graham Colditz, M.D., DrPH, MPH — Washington University School of Medicine
- Study coordinator: Graham Colditz, M.D., DrPH, MPH
- Email: colditzg@wustl.edu
- Phone: 314-454-7939
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Cholangiocarcinoma, Multiple Myeloma, Colon Cancer, Rectal Cancer, Participant engagement, Genetic testing, Colorectal cancer, Underrepresented populations